Non-Selective Beta Blocker Therapy Improves Survival in Patients Receiving Alfapump©

Jansen C, Wagner RM, Praktiknjo M, Chang J, Böhling N, Kaczmarek D, Lehmann J, Strassburg CP and Trebicka J

Department of Internal Medicine I, University of Bonn, Germany
Medical Department B, University Clinic Münster, Germany
European Foundation for Study of Chronic Liver Failure, Spain
#Both authors contributed equally to this work

^*Correspondance to: Christian Jansen 

 PDF  Full Text DOI: 10.25107/2474-1647.3596

Abstract

Background: Ascites is the common cause of decompensation in patients with cirrhosis. It has been ascertained that 5% to 10% of patients with end stage liver disease showed in case of compensation the develop of ascites every year. The alfapump© reduces the need for large volume paracentesis and can improve life quality. The aim of our study was to assess the role of the use of Non-Selective Beta-Blocker (NSBB) characteristics and outcomes of patients with cirrhosis receiving alfapump© and to find predictors of a longer life in a palliative concept. Methods: Seventeen (13 males) patients with liver cirrhosis receiving an alfapump© were included in this case-series. Clinical parameters were assessed before the insertion of the alfapump© and during follow-up. As part of the follow-up, all patients received the standard of care as recommended by European Association for the Study of the Liver and DGVS. Results: Could generally be identified as the cause of death. If the patients were stratified according to the use of a non-selective beta-blocker, we can see that the group taking non-selective beta blocker had a longer survival. These data to verify previous finding that NSBB in this very high-risk patient may delay infections and improve outcome. Conclusion: This study suggests a protective effect of NSBB in patients after implantation of an alfapump©. Although confirmation is needed, this may help management of patients receiving the device.

Keywords

Liver; Cirrhosis; Ascites; Alfapump©; Non-selective beta blocker

Cite the article

Jansen C, Wagner RM, Praktiknjo M, Chang J, Böhling N, Kaczmarek D, et al. Non-Selective Beta Blocker Therapy Improves Survival in Patients Receiving Alfapump©. Clin Surg. 2022; 7: 3596..